| Literature DB >> 26846309 |
Barbara Sandor1, Mickaël Marin2,3,4, Claudine Lapoumeroulie2,3,4, Miklos Rabaï1, Sophie D Lefevre2,3,4,5, Nathalie Lemonne6, Wassim El Nemer2,3,4, Anaïs Mozar4,7, Olivier Français8, Bruno Le Pioufle8, Philippe Connes4,7,8,9,10, Caroline Le Van Kim2,3,4,5.
Abstract
Vaso-occlusive crisis (VOC) is the main acute complication in sickle cell anaemia (SS) and several clinical trials are investigating different drugs to improve the clinical severity of SS patients. A phase III study is currently exploring the profit of Velopoloxamer in SS during VOCs. We analysed, in-vitro, the effect of poloxamer (P188) on red blood cell (RBC) properties by investigating haemorheology, mechanical and adhesion functions using ektacytometry, microfluidics and dynamic adhesion approaches, respectively. We show that poloxamer significantly reduces blood viscosity, RBC aggregation and adhesion to endothelial cells, supporting the beneficial use of this molecule in SS therapy.Entities:
Keywords: poloxamer; red blood cell; sickle cell anaemia
Mesh：
Substances：
Year: 2016 PMID： 26846309 DOI： 10.1111/bjh.13937
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998